2011 US submission for Genentech/Curis' vismodegib in basal cell carcinoma
This article was originally published in Scrip
Executive Summary
Contrary to some expectations,Genentech is on track to file for US approval this year of the Hedgehog pathway inhibitor, vismodegib (GDC-0449, RG3616), for advanced basal cell carcinoma (BCC), which it is developing with Curis.